T-889C IL-1α promoter polymorphism influences the response to oral cyclophosphamide in scleroderma patients with alveolitis

Clinical Rheumatology

Volumn 26, Issue 1, 2007, Pages 88-91

  Beretta, Lorenzo ^a   Cappiello, Francesca ^a   Barili, Morena ^a   Bertolotti, Francesca ^a   Scorza, Raffaella ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cyclophosphamide; Lung; Polymorphism; Systemic sclerosis

Indexed keywords

CYCLOPHOSPHAMIDE; INTERLEUKIN 1ALPHA; PREDNISONE;

ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG DOSE REDUCTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBROSING ALVEOLITIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESPIRATORY FAILURE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; SYSTEMIC SCLEROSIS; VITAL CAPACITY;

ADMINISTRATION, ORAL; ADULT; AGED; ALLELES; ANTIRHEUMATIC AGENTS; CASE-CONTROL STUDIES; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; INTERLEUKIN-1ALPHA; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 33845874906     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-006-0308-0     Document Type: Article

References (12)

1. Wells AU, Hansell DM, Corrin B, Harrison NK, Goldstraw P, Black CM et al (1992) High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 47:738-742
2. Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD et al (2005) Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 52:592-600
3. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 1932:947-954
4. Beretta L, Caronni M, Raimondi M, Ponti A, Viscuso T, Origgi L et al (2006) Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: Experience at one centre. Clin Rheumatol DOI:10.1007/s10067-006-0254-x
5. Clements P, Furst DE, Silver RM, Tashkin DP, Roth MD, Goldin J et al (2005) The Scleroderma Lung Study (SLS) shows the beneficial effects of cyclophosphamide (CYC) over placebo (PL) in systemic sclerosis (SSc) patients with active alveolitis. Arthritis Rheum 52:S624(Suppl)
6. Hutyrova B, Pantelidis P, Drabek J, Zurkova M, Kolek V, Lenhart K et al (2002) Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 165:148-151
7. Yucesoy B, Vallyathan V, Landsittel DP, Simenova P, Luster MI (2002) Cytokine polymorphisms in silicosis and other pneumoconioses. Mol Cell Biochem 234-235:219-224
8. Cappiello F, Barili M, Masciocchi M et al (2005) IL1-group gene polymorphisms and lung function in Italian scleroderma patients. Tissue Antigens 66:S396 (Suppl)
9. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-90
10. McDowell TL, Symons JA, Ploski R, Forre O, Duff GW (1995) A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum 38:221-228
11. Wells AU, Hansell DM, Rubens MB, King AD, Cramer D, Black CM et al (1997) Fibrosing alveolitis in systemic sclerosis: Indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 40:1229-1236
12. Hulkkonen J, Laippala P, Hurme M (2000) A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1 beta plasma levels in healthy individuals. Eur Cytokine Netw 11:251-255